The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Time course of nigrostriatal degeneration in parkinson's disease: A detailed study of influential factors in human brain amine analysis
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Federation Proceedings: Water and Electrolyte Losses in Cholera
Phillips, R. A. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.1982.tb05283.x · Cited by 3,934
A Method for the Fluorimetric Determination of Adrenaline and Noradrenaline in Tissues.1
BERTLER, Å., CARLSSON, A., & ROSENGREN., E. (1958) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1958.tb01627.x · Cited by 1,019
Fluorescence assay in biology and medicine
Udenfriend, S. (1962) · Medical Entomology and Zoology · Cited by 772
Fluorescence Assay in Biology and Medicine
Crounse, R. G. (1963) · Archives of Dermatology · doi:10.1001/archderm.1963.01590140145030 · Cited by 644
On the Presence of 3-Hydroxytyramine in Brain
CARLSSON, A., LINDQVIST, M., MAGNUSSON, T., & WALDECK, B. (1958) · Science · doi:10.1126/science.127.3296.471 · Cited by 634
(1973) · Elsevier eBooks · doi:10.1016/b978-0-120-78150-8.x5001-4 · Cited by 539
Anton, A. H., & Sayre, D. F. (1964) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)26864-1 · Cited by 508
Birkmayer, W., Riederer, P., Youdim, M. B. H., & Linauer, W. (1975) · Journal of Neural Transmission · doi:10.1007/bf01253131 · Cited by 363
Self-citationCoyle, J. T., & Snyder, S. H. (1969) · Science · doi:10.1126/science.166.3907.899 · Cited by 348
THE DISTRIBUTION OF SEROTONIN, 5‐HYDROXYTRYPTOPHAN DECARBOXYLASE, AND MONOAMINE OXIDASE IN BRAIN*
Bogdanski, D. F., Weissbach, H., & Udenfriend, S. (1957) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1957.tb12082.x · Cited by 346
Cited by
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Levodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
Riederer, P., Sofic, E., Rausch, W., Schmidt, B., Reynolds, G. P., Jellinger, K., & Youdim, M. B. H. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09150.x · Cited by 1,383
Self-citationDisease duration and the integrity of the nigrostriatal system in Parkinson’s disease
Kordower, J. H., Olanow, C. W., Dodiya, H. B., Chu, Y., Beach, T. G., Adler, C. H., Halliday, G. M., & Bartus, R. T. (2013) · Brain · doi:10.1093/brain/awt192 · Cited by 1,286
Clinical progression in Parkinson disease and the neurobiology of axons
Cheng, H., Ulane, C. M., & Burke, R. E. (2010) · Annals of Neurology · doi:10.1002/ana.21995 · Cited by 1,012
“Riederer and Wuketich analyzed postmortem data for caudate dopamine in relation to disease onset.(27) They studied 2 cohorts: 1 consisting of 27 patients with disease onset at 60 1 years, and a second consisting of 12 patients with onset at 73 1 years.”
MethodVolkow, N. D., Fowler, J. S., Wang, G., Hitzemann, R., Logan, J., Schlyer, D. J., Dewey, S. L., & Wolf, A. P. (1993) · Synapse · doi:10.1002/syn.890140210 · Cited by 924
‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease
Chan, C. S., Guzman, J. N., Ilijic, E., Mercer, J. N., Rick, C., Tkatch, T., Meredith, G. E., & Surmeier, D. J. (2007) · Nature · doi:10.1038/nature05865 · Cited by 904
Satz, P. (1993) · Neuropsychology · doi:10.1037//0894-4105.7.3.273 · Cited by 850
Sauer, H., & Oertel, W. H. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90605-x · Cited by 803
The Synaptic Function of α-Synuclein
Burré, J. (2015) · Journal of Parkinson's Disease · doi:10.3233/jpd-150642 · Cited by 573
Rate of cell death in parkinsonism indicates active neuropathological process
McGeer, P. L., Itagaki, S., Akiyama, H., & McGeer, E. G. (1988) · Annals of Neurology · doi:10.1002/ana.410240415 · Cited by 556
Lindvall, O. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520420033021 · Cited by 535
Parkinson's disease: pathophysiology
Agid, Y. (1991) · The Lancet · doi:10.1016/0140-6736(91)92989-f · Cited by 530
Gerlach, M., & Riederer, P. (1996) · Journal of Neural Transmission · doi:10.1007/bf01291788 · Cited by 498
Self-citationAxon degeneration in Parkinson's disease
Burke, R. E., & O'Malley, K. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2012.01.011 · Cited by 493
Bezard, E., Dovero, S., Prunier, C., Ravenscroft, P., Chalon, S., Guilloteau, D., Crossman, A. R., Bioulac, B., Brotchie, J. M., & Gross, C. E. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-17-06853.2001 · Cited by 483
Oxidative stress: Free radical production in neural degeneration
Götz, M. E., Künig, G., Riederer, P., & Youdim, M. B. H. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90055-8 · Cited by 482
Self-citationAETIOLOGY OF PARKINSON'S DISEASE
Calne, D., & William Langston, J. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90802-4 · Cited by 469
Imaging endogenous dopamine competition with [11C]raclopride in the human brain
Volkow, N. D., Wang, G., Fowler, J. S., Logan, J., Schlyer, D., Hitzemann, R., Lieberman, J., Angrist, B., Pappas, N., MacGregor, R., et al. (1994) · Synapse · doi:10.1002/syn.890160402 · Cited by 379
Regional changes of monoamines in cerebral cortex and subcortical structures of aging rhesus monkeys
Goldman-Rakic, P. S., & Brown, R. M. (1981) · Neuroscience · doi:10.1016/0306-4522(81)90053-1 · Cited by 354
Does levodopa slow or hasten the rate of progression of Parkinson’s disease?
Fahn, S., & and the Parkinson Study Group (2005) · Journal of Neurology · doi:10.1007/s00415-005-4008-5 · Cited by 347
Lateralization of Norepinephrine in Human Thalamus
Oke, A., Keller, R., Mefford, I., & Adams, R. N. (1978) · Science · doi:10.1126/science.663623 · Cited by 321
Teismann, P., & Ferger, B. (2001) · Synapse · doi:10.1002/1098-2396(200102)39:2<167::aid-syn8>3.0.co;2-u · Cited by 306
IMPLICATIONS OF COMBINED TREATMENT WITH 'MADOPAR' AND L-DEPRENIL IN PARKINSON'S DISEASE
Birkmayer, W., Riederer, P., Ambrozi, L., & Youdim, M. B. H. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91940-7 · Cited by 297
Self-citationCalcium, ageing, and neuronal vulnerability in Parkinson's disease
Surmeier, D. J. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70246-6 · Cited by 297
Central neurotransmitters and aging
Pradhan, S. N. (1980) · Life Sciences · doi:10.1016/0024-3205(80)90172-1 · Cited by 295
Hilker, R., Schweitzer, K., Coburger, S., Ghaemi, M., Weisenbach, S., Jacobs, A. H., Rudolf, J., Herholz, K., & Heiss, W.-D. (2005) · Archives of Neurology · doi:10.1001/archneur.62.3.378 · Cited by 293
Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons
Lundblad, M., Decressac, M., Mattsson, B., & Björklund, A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200575109 · Cited by 292
Neurochemical findings in the MPTP model of Parkinson's disease
Schmidt, N., & Ferger, B. (2001) · Journal of Neural Transmission · doi:10.1007/s007020100004 · Cited by 290
Oxidative damage in nucleic acids and Parkinson's disease
Nakabeppu, Y., Tsuchimoto, D., Yamaguchi, H., & Sakumi, K. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21191 · Cited by 290
The anterior olfactory nucleus in Parkinson's disease
Pearce, R. K. B., Hawkes, C. H., & Daniel, S. E. (1995) · Movement Disorders · doi:10.1002/mds.870100309 · Cited by 290
Striatal dopamine deficiency in parkinson's disease: Role of aging
Scherman, D., Desnos, C., Darchen, F., Pollak, P., Javoy‐Agid, F., & Agid, Y. (1989) · Annals of Neurology · doi:10.1002/ana.410260409 · Cited by 286
Yasuhara, T., Matsukawa, N., Hara, K., Yu, G., Xu, L., Maki, M., Kim, S. U., & Borlongan, C. V. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3719-06.2006 · Cited by 284
Kish, S. J., Shannak, K., Rajput, A., Deck, J. H. N., & Hornykiewicz, O. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb09766.x · Cited by 272
Winkler, C., Sauer, H., Lee, C. S., & Björklund, A. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-22-07206.1996 · Cited by 258
The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease
Ilijic, E., Guzman, J. N., & Surmeier, D. J. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.04.007 · Cited by 259
Diagnosis and the premotor phase of Parkinson disease
Tolosa, E., Gaig, C., Santamaría, J., & Compta, Y. (2009) · Neurology · doi:10.1212/wnl.0b013e318198db11 · Cited by 255
Surmeier, D. J., Guzman, J. N., Sanchez-Padilla, J., & Schumacker, P. T. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.045 · Cited by 236
Motor and non-motor circuit disturbances in early Parkinson disease: which happens first?
Blesa, J., Foffani, G., Dehay, B., Bezard, E., & Obeso, J. A. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00542-9 · Cited by 232
Parkinson’s disease as a result of aging
Rodriguez, M., Rodriguez‐Sabate, C., Morales, I., Sanchez, A., & Sabate, M. (2015) · Aging Cell · doi:10.1111/acel.12312 · Cited by 214
Zecca, L., Berg, D., Arzberger, T., Ruprecht, P., Rausch, W. D., Musicco, M., Tampellini, D., Riederer, P., Gerlach, M., & Becker, G. (2005) · Movement Disorders · doi:10.1002/mds.20550 · Cited by 214
Self-citationPhasic dopamine release in appetitive behaviors and drug addiction
Wanat, M., Willuhn, I., Clark, J., & Phillips, P. (2009) · Current Drug Abuse Reviewse · doi:10.2174/1874473710902020195 · Cited by 177
In vivo imaging of neuromelanin in Parkinson’s disease using18F-AV-1451 PET
Hansen, A. K., Knudsen, K., Lillethorup, T. P., Landau, A. M., Parbo, P., Fedorova, T., Audrain, H., Bender, D., Østergaard, K., Brooks, D. J., et al. (2016) · Brain · doi:10.1093/brain/aww098 · Cited by 128
Beuter, A., Lefaucheur, J.-P., & Modolo, J. (2014) · Clinical Neurophysiology · doi:10.1016/j.clinph.2014.01.006 · Cited by 107
Cho, Z., Oh, S., Kim, J., Park, S., Kwon, D., Jeong, H., Kim, Y., Chi, J., Park, C., Huston, J., et al. (2011) · Movement Disorders · doi:10.1002/mds.23465 · Cited by 87
Heng, N., Malek, N., Lawton, M. A., Nodehi, A., Pitz, V., Grosset, K. A., Ben‐Shlomo, Y., & Grosset, D. G. (2023) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13687 · Cited by 64
Wang, L., Liu, Y., Yan, S., Du, T., Fu, X., Gong, X., Zhou, X., Zhang, T., & Wang, X. (2020) · Aging and disease · doi:10.14336/ad.2019.0615 · Cited by 49
“However, it is generally accepted that bradykinesia appear in PD when dopamine neurons loss exceeds a threshold, 70–80% of striatal nerve terminals and 50–60% nigral neurons death [43, 44].”
BackgroundNoninvasive monitoring of plasma l-dopa concentrations using sweat samples in Parkinson's disease
Tsunoda, M., Hirayama, M., Tsuda, T., & Ohno, K. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.12.032 · Cited by 49
Watanabe, H., Dijkstra, J. M., & Nagatsu, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042009 · Cited by 48
Stievenard, A., Méquinion, M., Andrews, Z. B., Destée, A., Chartier-Harlin, M.-C., Viltart, O., & Vanbesien-Mailliot, C. C. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.11.021 · Cited by 39
Gerlach, M., Riederer, P., & Double, K. L. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.04.028 · Cited by 33
Self-citationDopamine triggers skeletal muscle tone by activating D1-like receptors on somatic motoneurons
Schwarz, P. B., & Peever, J. H. (2011) · Journal of Neurophysiology · doi:10.1152/jn.00230.2011 · Cited by 33
Gerlach, M., Grünblatt, E., & Lange, K. W. (2013) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-013-0105-y · Cited by 18
Brain aging phenomena in migrating sockeye salmon Oncorhynchus nerka nerka
Götz, M. E., Malz, C. R., Dirr, A., Blum, D., Gsell, W., Schmidt, S., Burger, R., Pohli, S., & Riederer, P. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-004-0257-1 · Cited by 11
Self-citation
Metadata
- Authors
- Riederer, P., & Wuketich, S.
- Venue
- Journal of Neural Transmission
- Published
- 1976-09
- Volume
- 38
- Issue
- 3-4
- Pages
- 277-301
- ISSN
- 0300-9564 (ISSN-L)
- 1435-1463
- OpenAlex
- W1976923181
- Cited by
- 577
- References
- 34
- FWCI
- 8.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.